CENMIRA Trademark

Trademark Overview


On Tuesday, January 7, 2020, a trademark application was filed for CENMIRA with the United States Patent and Trademark Office. The USPTO has given the CENMIRA trademark a serial number of 88749349. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 14, 2023. This trademark is owned by Teva Pharmaceutical Industries Limited. The CENMIRA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
cenmira

General Information


Serial Number88749349
Word MarkCENMIRA
Filing DateTuesday, January 7, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 14, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 19, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for the treatment of neurological disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, January 10, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceutical Industries Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressPetach Tikva 49131
IL

Party NameTeva Pharmaceutical Industries Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressPetach Tikva 49131
IL

Trademark Events


Event DateEvent Description
Monday, August 14, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, August 14, 2023ABANDONMENT - NO USE STATEMENT FILED
Thursday, June 29, 2023ASSIGNED TO EXAMINER
Thursday, February 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, February 2, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, February 2, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, February 2, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, January 26, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 25, 2023SOU EXTENSION 5 GRANTED
Monday, January 9, 2023SOU EXTENSION 5 FILED
Wednesday, January 25, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, January 9, 2023SOU TEAS EXTENSION RECEIVED
Saturday, July 16, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 14, 2022SOU EXTENSION 4 GRANTED
Thursday, July 14, 2022SOU EXTENSION 4 FILED
Thursday, July 14, 2022SOU TEAS EXTENSION RECEIVED
Thursday, July 7, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, July 7, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 7, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, January 8, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 6, 2022SOU EXTENSION 3 GRANTED
Thursday, January 6, 2022SOU EXTENSION 3 FILED
Thursday, January 6, 2022SOU TEAS EXTENSION RECEIVED
Thursday, July 15, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 13, 2021SOU EXTENSION 2 GRANTED
Tuesday, July 13, 2021SOU EXTENSION 2 FILED
Tuesday, July 13, 2021SOU TEAS EXTENSION RECEIVED
Friday, December 18, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 16, 2020SOU EXTENSION 1 GRANTED
Wednesday, December 16, 2020SOU EXTENSION 1 FILED
Wednesday, December 16, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, July 14, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 19, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 19, 2020PUBLISHED FOR OPPOSITION
Wednesday, April 29, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, April 10, 2020ASSIGNED TO LIE
Friday, April 3, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 1, 2020EXAMINER'S AMENDMENT ENTERED
Wednesday, April 1, 2020NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, April 1, 2020EXAMINERS AMENDMENT E-MAILED
Wednesday, April 1, 2020EXAMINERS AMENDMENT -WRITTEN
Friday, March 27, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 27, 2020NON-FINAL ACTION E-MAILED
Friday, March 27, 2020NON-FINAL ACTION WRITTEN
Thursday, March 26, 2020ASSIGNED TO EXAMINER
Friday, January 10, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, January 10, 2020NEW APPLICATION ENTERED